# US 2025/0146087 A1 · Tumor microbiome analysis as a prognostic indicator of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146087 A1
- Document ID: US20250146087A1
- Status: Published application
- Kind: A1
- Application number: 18/730,566
- Filed: 2023-01-18
- Published: 2025-05-08
- Earliest claimed: 2022-01-19
- Assignees: UEA Enterprises Limited
- Applicants: Uea Enterprises Limited
- Inventors: Colin Stephen Cooper; Daniel Simon Brewer; Rachel Hurst; Abraham Farag Salah Gihawi; Justin Joseph O'Grady; John Richard Wain; Emma Jane Meader; Ghanasyam Rallapalli
- Web page: https://patentgrep.com/patent/US20250146087A1

## CPC

- C12Q 1/689: for bacteria
- C12N 1/205: Bacterial isolates
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present invention relates to prostate cancer (PC), in particular the identification of certain bacteria in prostate cancer tissues or liquid biopsies and the use of such identification as a prognostic indicator of cancer progression. The present invention also relates to cultures of newly identified bacteria and means for identifying such bacteria in biological samples.

## Claims

### Claim 1

A method of providing a cancer prognosis in a patient based on the presence of one or more bacteria in a biological sample from the patient, comprising:
(a) detecting the presence of one or more bacteria selected from the genera Fenollaria, Ezakiella, Peptoniphilus, Porphyromonas, Anaerococcus and Fusobacterium in a biological sample from the patient,
(b) providing a prognosis for the patient, wherein the patient has a poor prognosis if one or more of the bacteria are present in the biological sample.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the one or more bacteria is selected from the genera Fenollaria, Peptoniphilus, Porphyromonas, Anaerococcus and Fusobacterium in a biological sample from the patient,

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2 comprising detecting the presence of bacteria from each of the genera Fenollaria, Peptoniphilus, Porphyromonas, Anaerococcus and Fusobacterium in a biological sample from the patient,

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the one or more bacteria are selected from: Fenollaria sporofastidiosus, Peptoniphilus rachelemmaiella, Peptoniphilus harei, Peptoniphilus coxii, Anaerococcus prevotii, Anaerococcus lactolyticus, Porphyromonas bobii, Porphyromonas asaccharolytica, Porphyromonas bennonis and Fusobacterium nucleatum.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1 to 4, wherein one or more of the bacteria are selected from: Fenollaria sporofastidiosus, Peptoniphilus rachelemmaiella, Peptoniphilus harei, Anaerococcus prevotii, Porphyromonas bobii, Porphyromonas asaccharolytica and Fusobacterium nucleatum.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein one or more of the bacteria are selected from: Fenollaria sporofastidiosus (identified by ECACC accession number 21092201 or DSMZ accession number DSM 34056), Peptoniphilus rachelemmaiella (identified by ECACC accession number 21092202 or DSMZ accession number DSM 34055) and Porphyromonas bobii (identified by ECACC accession number 21092204 or DSMZ accession number DSM 34063).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1 to 6, wherein a poor prognosis is associated with an increased risk of elevated rates of metastases.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1 to 7, wherein the biological sample is a urine sample, a semen sample, a prostatic exudate sample, or any sample containing macromolecules or cells originating in the prostate, a whole blood sample, a serum sample, saliva, or a biopsy (such as a prostate tissue sample or a tumour sample).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1 to 8 wherein the biological sample is a urine sample.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1 to 9, wherein the method is used to determine whether a patient should be biopsied.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1 to 10, wherein the biological sample is processed prior to determining the presence of the one or more bacteria in the biological sample.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method according to any one of claims 1 to 11, wherein the presence of the one or more bacteria is determined using quantitative polymerase chain reaction (qPCR) or a probe-based detection assay (such as NanoString®).

### Claim 13 (depends on 12)

The method according to claim 12, wherein the presence of the one or more bacteria is determined using quantitative polymerase chain reaction (qPCR) or a probe-based detection assay (such as NanoString®) using one or more primers comprising a nucleotide sequence selected from the list SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20.

### Claim 14

A method of detecting the presence of one or more bacteria selected from the genera Fenollaria, Peptoniphilus, Porphyromonas, Anaerococcus and Fusobacterium in a biological sample from the patient.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the one or more bacteria are selected from: Fenollaria sporofastidiosus, Peptoniphilus rachelemmaiella, Peptoniphilus harei, Peptoniphilus coxii, Anaerococcus prevotii, Anaerococcus lactolyticus, Porphyromonas bobii, Porphyromonas asaccharolytica, Porphyromonas bennonis and Fusobacterium nucleatum.

### Claim 16 (depends on 14, 15)

The method according to claim 14 or claim 15, wherein one or more of the bacteria are selected from: Fenollaria sporofastidiosus, Peptoniphilus rachelemmaiella, Peptoniphilus harei, Anaerococcus prevotii, Porphyromonas bobii, Porphyromonas asaccharolytica and Fusobacterium nucleatum.

### Claim 17 (depends on 14, 15, 16)

The method according to any one of claims 14 to 16, wherein one or more of the bacteria are selected from: Fenollaria sporofastidiosus (identified by ECACC accession number 21092201 or DSMZ accession number DSM 34056), Peptoniphilus rachelemmaiella (identified by ECACC accession number 21092202 or DSMZ accession number DSM 34055) and Porphyromonas bobii (identified by ECACC accession number 21092204 or DSMZ accession number DSM 34063).

### Claim 18 (depends on 14, 15, 16, 17)

The method according to any one of claims 14 to 17, wherein the biological sample is a urine sample, a semen sample, a prostatic exudate sample, or any sample containing macromolecules or cells originating in the prostate, a whole blood sample, a serum sample, saliva, or a biopsy (such as a prostate tissue sample or a tumour sample).

### Claim 19 (depends on 14, 15, 16, 17, 18)

The method according to any one of claims 14 to 18 wherein the biological sample is a urine sample.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The method according to any one of claims 14 to 19, wherein the presence of the one or more bacteria is determined using quantitative polymerase chain reaction (qPCR) or a probe-based detection assay (such as NanoString®).

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 14 to 20, wherein the presence of the one or more bacteria is determined using quantitative polymerase chain reaction (qPCR) or a probe-based detection assay (such as NanoString®) using one or more primers comprising a nucleotide sequence selected from the list SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20.

### Claim 22

The method according to any preceding claim wherein the sample is from a human.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of treating a cancer in a patient in need thereof, comprising providing a prognosis of a patient's cancer using a method as defined in any one of claims 1 to 12, and administering to the patient a therapy for treating cancer.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 22)

The method according to any one of claims 1 to 12 and 22Error!Reference source not found., wherein the cancer is prostate cancer.

### Claim 25 (depends on 22, 23)

The method according to any one of claims 22 to 23, wherein the therapy for cancer comprises surgery, brachytherapy, active surveillance, chemotherapy, hormone therapy, immunotherapy and/or radiotherapy.

### Claim 26

A cell culture comprising bacteria Varibaculum prostatecancerukia identified by ECACC deposit number 21092203 or DSMZ accession number DSM 34057.

### Claim 27

A cell culture comprising bacteria Fenollaria sporofastidiosus identified by ECACC deposit number 21092201 or DSMZ accession number DSM 34056.

### Claim 28

A cell culture comprising bacteria Peptoniphilus rachelemmaiella identified by ECACC deposit number 21092202 or DSMZ accession number DSM 34055.

### Claim 29

A cell culture comprising bacteria Porphyromonas bobii identified by ECACC deposit number 21092204 or DSMZ accession number DSM 34063.

### Claim 30 (depends on 26, 27, 28, 29)

Use of a cell culture according to any one of claims 26 to 29 in providing a prognosis of cancer in a patient.
